{"id":12689,"date":"2009-01-08T10:30:00","date_gmt":"2009-01-08T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/aboutpharma-rassegna-stampa-dal-070109-al-080109\/"},"modified":"2009-01-08T10:30:00","modified_gmt":"2009-01-08T09:30:00","slug":"aboutpharma-rassegna-stampa-dal-070109-al-080109","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aboutpharma-rassegna-stampa-dal-070109-al-080109\/","title":{"rendered":"ABOUTPHARMA, Press Review from 07\/01\/09 to 08\/01\/09"},"content":{"rendered":"<p><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">Press Review from<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\"> <strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">07\/01\/09<\/span><\/font><\/strong><\/strong><\/span><\/font><strong><strong><font face=\"Times New Roman\" color=\"#ff0000\"><span style=\"color: red\">&nbsp;<\/span><\/font><\/strong><\/strong><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">to the<\/span><\/font><font color=\"#ff0000\"><span style=\"color: red\">&nbsp;<\/span><\/font><\/strong><\/strong><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">08\/01\/09<\/span><\/font><font color=\"#ff0000\"><span style=\"color: red\">&nbsp;<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><\/font><\/p>\n<p><strong><font face=\"Arial\" color=\"#000080\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: navy; font-family: Arial\">&nbsp;<\/span><\/font><\/strong><\/p>\n<p><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span lang=\"EN-GB\" style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Wyeth: possible acquisition of Crucell<\/span><\/font><\/strong><\/p>\n<p><font face=\"Arial\" size=\"2\"><span lang=\"EN-GB\" style=\"font-size: 10pt; font-family: Arial\">(The Financial Times online, The Wall Street Journal online, Les Echos online \u2013 January 8, 2009)<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">The American Wyeth has begun negotiations for the acquisition of the Dutch biopharmaceutical Crucell, specialized in the production of vaccines. According to some rumors, the operation, which would allow Wyeth to strengthen its position in this sector, could be worth around 1.35 billion dollars.<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a target=\"_blank\" href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=18559\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/<wbr><\/wbr>news.asp?id=18559<\/a><\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">&nbsp;<\/span><\/font><\/p>\n<p><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Rome: false recipes, interrogations scheduled for January 19th<\/span><\/font><\/strong><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Il Messaggero Rome: page 37 \u2013 8 January 2009)<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">On January 19, the investigating magistrate of the Court of Rome, Maria Teresa Covatta, will interrogate the 14 suspects (doctors and pharmacists) last December 2. The investigation concerns false prescriptions and prescriptions issued to the detriment of the NHS, for a scam that exceeds 10 million euros.<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a target=\"_blank\" href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=18558\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/<wbr><\/wbr>news.asp?id=18558<\/a><\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">&nbsp;<\/span><\/font><\/p>\n<p><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Use: Allergan launches a product to lengthen eyelashes<\/span><\/font><\/strong><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Les Echos online \u2013 January 8, 2009)<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">On December 24, 2008, Allergan obtained FDA approval for Latisse (bimatoprost), a pr<\/p>","protected":false},"excerpt":{"rendered":"<p>Rassegna Stampa dal 07\/01\/09&nbsp;al&nbsp;08\/01\/09&nbsp; &nbsp; Wyeth: possibile acquisizione di Crucell (The Financial Times online, The Wall Street Journal online, Les Echos online &#8211; 8 gennaio 2009) L&#8217;americana Wyeth ha iniziato le trattative per l&#8217;acquisizione della biofarmaceutica olandese Crucell, specializzata nella produzione di vaccini. Secondo alcune indiscrezioni l&#8217;operazione, che permetterebbe a Wyeth di rafforzare la sua &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12689","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12689"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12689\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}